Prof Salles provided an update on the ongoing first-line follicular lymphoma (FL) studies, demonstrating how analysis of the GALLIUM study data regarding the use of different chemotherapy backbones consistently showed the benefits of obinutuzumab (G) chemotherapy (G-chemo) versus rituximab (R) chemotherapy (R-chemo) in FL patients.
In this issue
Latest articles
All articles![](https://www.emjreviews.com/wp-content/uploads/2024/04/Niamh-OConnell-Thumbnail-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/03/Pier-Mannucci-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/03/Immunoglobin-D-Multiple-Myeloma-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/02/Coexistence-of-Sickle-Cell-Thalassaemia-with-Overlapping-Syndrome-940x564.png)